Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.
Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Asquith CRM, et al. Among authors: johnson gl. Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357. Epub 2024 Apr 2. Eur J Med Chem. 2024. PMID: 38636130 Free PMC article.
Illuminating function of the understudied druggable kinome.
Gomez SM, Axtman AD, Willson TM, Major MB, Townsend RR, Sorger PK, Johnson GL. Gomez SM, et al. Among authors: johnson gl. Drug Discov Today. 2024 Mar;29(3):103881. doi: 10.1016/j.drudis.2024.103881. Epub 2024 Jan 11. Drug Discov Today. 2024. PMID: 38218213 Review.
Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships.
Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Asquith CRM, et al. Among authors: johnson gl. bioRxiv [Preprint]. 2023 Dec 28:2023.12.28.573261. doi: 10.1101/2023.12.28.573261. bioRxiv. 2023. Update in: Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357 PMID: 38234837 Free PMC article. Updated. Preprint.
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2.
Karim M, Mishra M, Lo CW, Saul S, Cagirici HB, Tran DHN, Agrawal A, Ghita L, Ojha A, East MP, Gammeltoft KA, Sahoo MK, Johnson GL, Das S, Jochmans D, Cohen CA, Gottwein J, Dye J, Neff N, Pinsky BA, Laitinen T, Pantsar T, Poso A, Zanini F, Jonghe S, Asquith CRM, Einav S. Karim M, et al. Among authors: johnson gl. bioRxiv [Preprint]. 2024 Apr 17:2024.04.15.589676. doi: 10.1101/2024.04.15.589676. bioRxiv. 2024. PMID: 38659941 Free PMC article. Preprint.
Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinome.
East MP, Sprung RW, Okumu DO, Olivares-Quintero JF, Joisa CU, Chen X, Zhang Q, Erdmann-Gilmore P, Mi Y, Sciaky N, Malone JP, Bhatia S, McCabe IC, Xu Y, Sutcliffe MD, Luo J, Spears PA, Perou CM, Earp HS, Carey LA, Yeh JJ, Spector DL, Gomez SM, Spanheimer PM, Townsend RR, Johnson GL. East MP, et al. Among authors: johnson gl. bioRxiv [Preprint]. 2024 Oct 4:2024.10.04.614143. doi: 10.1101/2024.10.04.614143. bioRxiv. 2024. PMID: 39464086 Free PMC article. Preprint.
Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies.
Joisa CU, Chen KA, Beville S, Stuhlmiller T, Berginski ME, Okumu D, Golitz BT, Johnson GL, Gomez SM. Joisa CU, et al. Among authors: johnson gl. bioRxiv [Preprint]. 2023 Aug 3:2023.08.01.551346. doi: 10.1101/2023.08.01.551346. bioRxiv. 2023. Update in: Pac Symp Biocomput. 2024;29:276-290. PMID: 37577663 Free PMC article. Updated. Preprint.
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium. Angus SP, et al. Among authors: johnson gl. Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046. Neuro Oncol. 2018. PMID: 29982664 Free PMC article.
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B. Prasath V, et al. Among authors: johnson gl. Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39644403
461 results